Phaseline

Companies › Tern Therapeutics

Tern Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TTX-381
AAV9-mediated hCLN2 gene therapy
CLN2Phase 1Neuronal Ceroid Lipofuscinosis Type 2Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05791864TTX-381Phase 1Neuronal Ceroid Lipofuscinosis Type 2Metabolic and endocrineDec 2026

Targets

CLN2 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.